Bio E s Covid-19 vaccine candidate gets SEC nod for phase-III trials
Top Searches
Bio E s Covid-19 vaccine candidate gets SEC nod for phase-III trials
Swati Bharadwaj / TNN / Apr 24, 2021, 15:39 IST
FacebookTwitterLinkedinEMail
Two shots of the intramuscular vaccine were administered 28 days apart as part of the study that evaluated the safety and immunogenicity of the vaccine candidate. (Representative image)
HYDERABAD: Vaccine maker Biological E Ltd on Saturday said it has received approval of the subject expert committee (SEC) of the Central Drugs Standard Control Organization (CDSCO) to start Phase III clinical trials of its Covid-19 subunit vaccine candidate, that it is developing with the Texas-based Baylor Medical College.
Share this -
copied
Dr. Peter Hotez, co-director of the Texas Children s Hospital Center for Vaccine Development and dean of the National School of Tropical Medicine, joins Ali Velshi to discuss the pause on the Johnson & Johnson vaccine in the United States after the discovery of 6 rare cases of blood clotting in women who were immunized with the shot. The goal, says Hotez, is to identify a specific group who might be at higher risk, and that requires a little time. “Even though the U.S. Has other options, many countries don t. For many countries, all they have are the J & J, AstraZeneca vaccine and the Russian Sputnik V vaccine,” all of which are non-mNRA and have the potential to behave similarly. Says Hotez, “It is critical to sort this out not only to protect American citizens, but to protect the world.”April 17, 2021
Dr Peter Hotez: The FDA and CDC really had no choice but to pause Johnson & Johnson vaccine msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
by Tyler Durden
Wednesday, Apr 14, 2021 - 11:20 PM
A few weeks ago, when President Biden held his first press conference since taking office, he promised that 200 million adults will have received at least one vaccine jab by the time his first 100 days have finished - a doubling of his initial target of 100M. Yet, in close to 130 countries, representing a population of 2.5 billion people, not a single adult has received a dose.
The reasons why can be traced back to one man: Bill Gates. Gates has been warning about the dangers of a pandemic for years - since long before COVID first emerged in Wuhan. And when the pandemic struck and talk first turned to vaccine, one issue that was notably left out of the discussion was who deserved the proper credit, and the proper payment. As the New Republic reports in its latest piece in a series attacking the Bill Gates myth that he and the Gates Foundation are the world s capitalist saviors - ready and eager to save poorer nations from the pand